Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy-Reference-Cited by-同舟云学术

Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy

Published:2023-01-12 Issue:2 Volume:198 Page:207-215
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Han Sangwon,Lee Sae Byul,Gong Gyungyub,Lee Jungbok,Chae Sun Young,Oh Jungsu S.,Moon Dae Hyuk^ORCID

Funder

Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06852-5.pdf

Reference45 articles.

1. Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P (2020) Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw Open 3(8):e2013226. https://doi.org/10.1001/jamanetworkopen.2020.13226

2. Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8

3. Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/S0140-6736(11)61625-5

4. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194–1220. https://doi.org/10.1093/annonc/mdz189

5. Gradishar WJ, Moran MS, Abraham J et al Breast Cancer, Version 5.2021, NCCN Clinical Practice Guidelines in Oncology

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer;Clinical and Translational Oncology;2023-10-17

2. High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer;Breast Cancer Research and Treatment;2023-02-03

3. Molecular imaging as biomarker for treatment response and outcome in breast cancer;Therapeutic Advances in Medical Oncology;2023-01